• Product NameDRAK1 Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAffinity chromatography purified via peptide column
• ApplicationsELISA WB ICC
• Species ReactivityHu
• SpecificityNo cross responses to DRAK2, DAP or ZIP kinases.
• Immunogen TypePeptide
• Immunogen DescriptionRaised against a peptide corresponding to amino acids near the amino terminus of human DRAK1.
• Target NameDRAK1
• Accession No. Q9UEE5
• UniprotQ9UEE5
• Gene ID9263;
• Concentration 1mg/ml
• Formulation Supplied in PBS containing 0.02% sodium azide.
• Storage Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

• Predicted MW: 50 kd
  

Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 for DAP kinase-related apoptosis-inducing protein kinases. DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK1 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK1 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.

• Western blot analysis of DRAK1 in (A) MOLT4 and (B) A431 whole cell lysates with DRAK1 antibody at 1 ug/mL.
• Immunocytochemistry staining of MOLT4 cells using DRAK1 antibody at 2 ug/mL.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting